VISUfarma is a pan-European ophthalmic specialty pharmaceutical company headquartered in Amsterdam, Netherlands. Founded in 2016, the company specializes in the development and commercialization of innovative pharmaceutical products and medical devices for eye health. In September 2025, it was announced that global pharmaceutical firm Lupin Limited would acquire VISUfarma for approximately €190 million to expand its European ophthalmology portfolio.
Core Operations and Market Presence
Business Model:
VISUfarma operates as an ophthalmic specialty company, bringing global therapeutic innovation to the European market.
Geographic Reach:
The company has a direct sales presence in major European markets, including Italy, Germany, Spain, France, and the United Kingdom. It also distributes products to over 20 countries globally through exclusive partnerships.
Financial Performance:
In 2024, the company generated approximately €48 million in revenue across its core markets.
Workforce:
VISUfarma employs approximately 175+ people.
Product Portfolio and Therapeutic Areas
VISUfarma provides a wide range of preservative-free OTx (over-the-counter), Rx (prescription), and food supplement products. Key therapeutic areas include:
Dry Eye Syndrome:
Offers products like VisuXL (a “smart gel” providing 12-hour protection) and the Xailin range for various levels of dry eye severity.
Glaucoma:
Focuses on neuroprotection as a complementary treatment. Its CoQun range (including CoQun Combo) combines Coenzyme Q10 and Citicoline to support optic nerve health and mitochondrial energy.
Eyelid Hygiene & MGD:
Managed through brands like Naviblef, VisuEVO Wipes, and MeiboPatch (a warm eye compress) for treating blepharitis and meibomian gland dysfunction.
Retinal Health:
Provides food supplements such as VISUcomplex Plus and Visioprev to support patients with age-related macular degeneration (AMD).
History and Strategic Origins
Formation:
Created by the healthcare investment firm GHO Capital through the merger of Italian firm Visufarma SpA and the European commercial operations of France-based Nicox SA.
Development:
The company significantly invested in upskilling pan-European functions such as supply chain, marketing, and R&D to build a unified international business.
Acquisition (2025):
Lupin’s subsidiary, Nanomi B.V., signed the agreement to acquire VISUfarma, with the deal expected to close by the end of 2025.